- Twist Bioscience ( NASDAQ: TWST ) is licensing a suite of its VHH antibody libraries to South Korea's Ildong Pharmaceutical to discover and develop antibodies for use in immuno-oncology therapies.
- Under the agreement, Ildong will license a suite of Twist’s VHH libraries for three years and will use the them for research and development activities.
- South San Francisco, Calif.-based Twist will receive an upfront payment, annual maintenance fees and additional money for success-based clinical and regulatory milestones, plus royalties on product sales.
- "We believe our VHH libraries are extremely versatile in their applications developing novel and next generation therapies. Because they are significantly smaller than a traditional human antibody, they can be combined with other technologies, or used on their own for development of effective therapies,” said Twist ( TWST ) Co-Founder and CEO Emily Leproust.
For further details see:
Twist Bioscience, Ildong team up to discover antibodies for cancer therapies